or Try an Advanced Search...

    Technical Analysis for PYXS - Pyxis Oncology, Inc.

    Grade Last Price % Change Price Change
    C 3.76 5.62% 0.20
    PYXS closed up 5.62 percent on Friday, November 1, 2024, on 87 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Up Up
    Historical PYXS trend table...
    Date Alert Name Type % Chg
    Crossed Above 50 DMA Bullish 0.00%
    180 Bullish Setup Bullish Swing Setup 0.00%
    Inside Day Range Contraction 0.00%
    Fell Below 50 DMA Bearish 5.62%
    Calm After Storm Range Contraction -1.57%
    NR7 Range Contraction -1.57%
    Inside Day Range Contraction -1.57%
    Calm After Storm Range Contraction -0.79%
    Upper Bollinger Band Walk Strength -0.79%
    Inside Day Range Contraction -0.79%
    Older End-of-Day Signals for PYXS ...

       Recent Intraday Alerts

    Alert Time
    Rose Above 10 DMA about 18 hours ago
    60 Minute Opening Range Breakout about 18 hours ago
    60 Minute Opening Range Breakdown about 19 hours ago
    Possible NR7 about 19 hours ago
    Possible Inside Day about 19 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    PYXS Chart by TradingView
    Basic chart:

    Profile

    Pyxis Oncology, Inc., a preclinical stage biotechnology company, engages in the development of antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immunotherapies to treat cancers. Its preclinical products pipeline includes PYX-201, a site-specific investigational ADC targeting onco-fetal fibronectin extradomain-B for the treatment of non-small cell lung cancer; PYX-202, a site-specific investigational ADC targeting delta like non-canonical notch ligand 1 to treat small cell lung cancer, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational site-specific ADC targeting CD123 for the treatment of acute myeloid leukemia and other blood cancers. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Cancer Clinical Medicine Immunology Solid Tumors Immunotherapy Cancer Treatment Monoclonal Antibody Acute Myeloid Leukemia Immunotherapies Non Small Cell Lung Cancer Antineoplastic Drugs Small Cell Lung Cancer Antibody Drug Conjugate Treatment Of Acute Myeloid Leukemia Blood Cancers Soft Tissue Sarcoma Treatment Of Non Small Cell Lung Cancer

    Is PYXS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Sep 13 Moment Of Truth Approaches For Pyxis Oncology
    Aug 29 Pyxis Oncology to Participate in Two Upcoming Investor Conferences
    Aug 15 Pyxis Oncology GAAP EPS of -$0.29
    Aug 14 Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024
    Aug 8 Pyxis Oncology draws Buy at Stifel on lead asset
    Jul 29 Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference
    Jun 28 Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    Jun 20 Institutional owners may ignore Pyxis Oncology, Inc.'s (NASDAQ:PYXS) recent US$25m market cap decline as longer-term profits stay in the green
    Jun 10 Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger
    Jun 10 Pyxis Oncology: Promising Research Amid Cash Constraints
    See more PYXS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 6.85
    52 Week Low 1.35
    Average Volume 489,361
    200-Day Moving Average 4.01
    50-Day Moving Average 3.57
    20-Day Moving Average 3.49
    10-Day Moving Average 3.69
    Average True Range 0.23
    RSI (14) 55.95
    ADX 24.48
    +DI 28.70
    -DI 17.69
    Chandelier Exit (Long, 3 ATRs) 3.50
    Chandelier Exit (Short, 3 ATRs) 3.69
    Upper Bollinger Bands 3.98
    Lower Bollinger Band 3.01
    Percent B (%b) 0.78
    BandWidth 27.61
    MACD Line 0.07
    MACD Signal Line 0.03
    MACD Histogram 0.0313
    Fundamentals Value
    Market Cap 166.65 Million
    Num Shares 44.3 Million
    EPS -2.56
    Price-to-Earnings (P/E) Ratio -1.47
    Price-to-Sales 0.00
    Price-to-Book 1.19
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 4.06
    Resistance 3 (R3) 4.03 3.90 4.01
    Resistance 2 (R2) 3.90 3.82 3.92 3.99
    Resistance 1 (R1) 3.83 3.78 3.87 3.86 3.98
    Pivot Point 3.70 3.70 3.72 3.72 3.70
    Support 1 (S1) 3.63 3.62 3.67 3.66 3.54
    Support 2 (S2) 3.50 3.58 3.52 3.53
    Support 3 (S3) 3.43 3.50 3.51
    Support 4 (S4) 3.46